- PRGF - ENDORET®
- Medical specialties
- BTI APNIA®
- Diagnosis
- Treatment
Quick links
What is PRGF - ENDORET® technology?
PRGF - ENDORET® is a technology designed to obtain plasma rich in growth factors (PRGF). These autologous proteins derived from blood stimulate the regeneration of different types of tissue.
What is PRGF - ENDORET® technology?
Hundreds of endogenous proteins influence tissue repair processes, including angiogenesis, chemotaxis and cell proliferation. No exogenous agent can effectively act on all of these processes.
PRGF - ENDORET® technology provides the means to obtain plasma rich in growth factors from blood, enabling its appropriate application at the site of injury through the preparation of different formulations.
How does PRGF - ENDORET® technology work in tissue regeneration?
The use of this therapeutic technology activates multiple biological mechanisms involved in tissue regeneration processes:
Regulates angiogenesis
Stimulates cell migration
Increases cell proliferation
Reduces inflammation and pain
Stimulates the autocrine and paracrine secretion of growth factors
Inhibits fibrosis
PRGF - ENDORET® technology provides controlled activation in tissue regeneration.
The activation process in PRGF - ENDORET® technology reverses the anticoagulant effect and triggers the controlled release of platelet growth factors. This achieves immediate bioavailability after application together with a continuous, prolonged supply of the factors retained within the fibrin membrane.
Advantages of PRGF - ENDORET®
Optimal platelet concentration
Platelet concentration 2–3 times the baseline level, with a balance between platelet-derived and plasma growth factors, enabling optimal regeneration.
Leucocyte- and inflammatory protein-free formulation
It reduces inflammation, pain and tissue fibrosis, and preserves the integrity of the fibrin matrix over time.
Controlled activation
It promotes the release of growth factors from platelets and induces polymerisation of the fibrin matrix.
Dual effect and bioavailability
Immediate bioavailability due to the effect of the growth factors at the time of application, with prolonged activity over time thanks to the fibrin matrix.
Patient safety
As it is an autologous product, there is no risk of incompatibility or rejection for the patient.
Reproducibility
A strictly defined protocol for the preparation process and its clinical application guarantees reproducibility of the final product.
Versatility
PRGF - ENDORET® technology enables the preparation of different formulations tailored to each clinical need.
Supported by clinical evidence
BTI has the largest body of published clinical evidence worldwide in this field, 30 supporting its efficacy with more than 0 scientific publications across different areas of medicine.
Safety and regulatory compliance
The PRGF - ENDORET® technology kits contain all the components required to prepare the final product and comply with all regulatory requirements established by the competent authorities at national and international level.
Ongoing training
BTI certifies and trains its clients in the rigorous application of this technology through defined protocols designed to ensure regulatory compliance and the reproducibility of outcomes.
Why use PRGF - ENDORET® rather than other PRPs?
PRP preparation systems are technologies that follow a specific protocol and include both the materials and the technique used to obtain the final product. Each technology is different and, therefore, each PRP is different. Efficacy depends critically on adherence to the defined protocol. Accordingly, each PRP system demonstrates its efficacy only through the use of a specific material and a specific preparation technique, and its results cannot be extrapolated to other PRPs.
The PRGF - ENDORET® protocol allows the leucocyte fraction (buffy coat) to be excluded. The absence of leucocytes prevents the release of pro-inflammatory interleukins and metalloproteinases, significantly reducing pain, inflammation and premature degradation of the fibrin matrix, while also preventing fibrous tissue formation.
Activation with ENDORET® Activator, included in each kit, is the essential biological step required to trigger the regenerative potential of the plasma. This triggers the release of platelet growth factors and induces polymerisation of the fibrin membrane, providing a long-term therapeutic effect.
Frequently asked questions
Are all PRPs the same?
No, not all platelet-rich plasmas are the same. The clinical efficacy of a PRP is determined principally by three key parameters: achieving an optimal platelet concentration, leucocyte content, and ex vivo platelet activation. PRP preparation systems are technologies that follow a specific protocol and include both the materials and the preparation technique. Each technology is different and, therefore, each PRP obtained is different. Accordingly, each PRP system demonstrates its efficacy only through the use of its specific material and technique, and its clinical results cannot be extrapolated to other brands or to in-house PRPs available on the market.
Why is the plasma obtained using PRGF - ENDORET® technology free of leucocytes?
The protocol and centrifugation conditions of PRGF - ENDORET® technology, as a closed and standardised system, allow the leucocyte fraction to be excluded with precision. Excluding leucocytes is essential because it prevents the release of pro-inflammatory proteins. Their absence significantly reduces pain, inflammation and tissue fibrosis in the patient. In addition, in the absence of leucocytes, the integrity of the fibrin matrix is preserved over time, preventing its premature degradation.
Why is it necessary to activate the plasma obtained?
Controlled ex vivo activation, for example with ENDORET® Activator, is the essential biological step required to release the full platelet content, which cannot be achieved without this step. This activation promotes the immediate release of platelet growth factors, achieving a greater biological response, and simultaneously induces polymerisation of the fibrin matrix. This produces a dual effect: immediate bioavailability to initiate regeneration and a prolonged therapeutic effect over time owing to retention within the fibrin meshwork.
Are the PRGF - ENDORET® technology kits compatible with any type of centrifuge?
No. To guarantee the efficacy, safety and reproducibility of clinical results, the system requires the exclusive use of BTI centrifuges. These feature a pre-set acceleration and braking programme, which is essential for preparing the final product and obtaining the desired clinical results.
Does PRGF - ENDORET® technology comply with current regulatory requirements?
Our products are developed under EN ISO 13485 and MDSAP quality management systems, ensuring strict compliance with the regulatory requirements of each country in which we operate.
What components are included in the single-use PRGF - ENDORET® technology kits?
The single-use kits include all the materials required to prepare the final product, from collection through to activation.
What do I need to start using PRGF - ENDORET® technology?
BTI certifies its clients’ specific training in the use of this technology for the correct application of a strictly defined and validated protocol, ensuring reproducibility of results and compliance with current healthcare regulations.
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Contact us
¡Gracias!
A paragraph is a self-contained unit of a discourse in writing dealing with
a particular point or idea. Paragraphs are usually an expected part of
formal writing, used to organize longer prose.